secwatch.observer — SEC 8-K summary
======================================

Issuer:     TALPHERA, INC. (TLPH)
CIK:        0001427925
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001437749-23-030955
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AcelRx Q3 net loss $1.4M; Niyad gets FDA IDE approval, registrational study to start Q4
--------------------------------------------------------------------------------

- Net loss from continuing ops $1.4M ($0.08/sh); revenue $0.1M from DSUVIA royalty.
- Cash $13.4M at Sep 30; Oxford senior debt fully repaid in Q2 2023.
- FDA IDE approval for Niyad (regional anticoagulant for dialysis); NEPHRO study to start Q4, data mid-2024.
- July private placement raised $10M, with potential $16.3M additional upon milestone warrants.
- Combined R&D and SG&A expenses $3.4M, down from $4.5M YoY; headcount reduction offset by Niyad costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427925/000143774923030955/0001437749-23-030955-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427925/000143774923030955/acrx20231107_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-030955

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer